Editas Announced USPTO Reaffirms Broad's CRISPR Patent Rights

The U.S. Patent and Trademark Office ruled in favor of the Broad Institute in the dispute over who first invented CRISPR/Cas9 use in human cells, representing a direct setback for Editas Medicine's IP position. The decision increases legal and commercial uncertainty for Editas, potentially constraining its ability to assert patents or extract licensing revenue and putting pressure on valuation until appeals or further rulings provide resolution.

Analysis

The U.S. Patent and Trademark Office ruled in favor of the Broad Institute in the dispute over who first invented CRISPR/Cas9 use in human cells, representing a direct setback for Editas Medicine's IP position. The decision increases legal and commercial uncertainty for Editas, potentially constraining its ability to assert patents or extract licensing revenue and putting pressure on valuation until appeals or further rulings provide resolution.